Insecticides India Ltd Q1 FY27 Earnings Call Summary

Revenue

Margin

Demand

Guidance

Tone

Event Participants

Executives

4 Rajesh Kumar Aggarwal, Sandeep Kumar Aggarwal, Devendra Kumar Ray, Dushyant Sood

Analysts

6 Kunal Tokas, Madhur Rathi, Nivesh Verma, Paul Sharma, Prashant Biyani, Ramesh, Sonia Raghuvanshi

Financials & KPIs

Metric	Reported	Commentary
Revenue from Operations	Value grew ~2%	Volume degrowth of 13%, offset by ~2% price realization increase; impacted by delayed season and uneven monsoon
Gross Profit	₹193 crores	Up 93% YoY; gross margin expanded 240 bps to 31.6% from 21.0%
EBITDA Margin	9.1%	Down 310 bps from 12.2% YoY due to lower operating leverage and elevated costs
PAT Margin	7.3%	Down 110 bps from 8.4% YoY
Segment Mix (B2C/B2B/Export)	64%/34%/2%	Shift from year-ago mix of 75%/17%/8%; B2B and export traction improved, B2C share lower
Premium Products (Maharatna + Focus Maharatna) Contribution	64% of B2C	Down from 68% YoY; management targets 70% in 3-4 years
New Product Revenue (Corteva launches)	₹5.50 crores	Revenue from two products launched during the quarter
Patented Product Revenue	₹70 crores	Down from ₹97 crores YoY due to reduction in sales of Monocrotophos (Lastmon)
Combination Product Revenue	₹98 crores	Down from ₹144 crores YoY
In-licensing Revenue	₹46 crores	Up from ₹36 crores YoY

Geographic & Segment Commentary

B2C Business: Revenue declined due to delayed kharif season, with insecticide share at 33%, herbicide at 59%, fungicide at 5%, and PGR at 3% of B2C sales. Herbicide growth is expected to register in Q2 as delayed demand from Q1 pushes through.
B2B Business: Grew ~10% YoY, outperforming B2C, supported by both technical sales and white-labeling opportunities. Management expects B2B to grow faster than B2C in Q2 as well.
International/Exports: Contribution fell to 2% of total sales (from 8% YoY), but management reports momentum in registrations and partnerships across Latin America, Europe, and ASEAN, with a calibrated approach to scaling.
Kharif Season (South India): Rice sowing remains delayed in Karnataka, Andhra Pradesh, and Tamil Nadu, but reservoir levels are improving. Cotton and wheat area reduced; groundnut and chilli are expected to be major crops for the southern states.

Company-Specific & Strategic Commentary

Brand & Portfolio Premiumization: Focus Maharatna and Maharatna portfolio contributed 64% of B2C business; management targets 70% in the next 3-4 years. Gross margins are differentiated: generics 10-15%, Maharatna ~30%, and Focus Maharatna 35-40%+.
Product Launches & Partnerships: Launched Grenovia and Espano in collaboration with Corteva; partnerships with Nissan and OET Agrio progressing. More than 30 product pipeline launches expected over the next two years, including mixtures and new AIs.
CARO Research: Revenue crossed ₹40 crores already commercialized; expanding portfolio, distribution footprint, and B2B/PET pack opportunities as a second growth platform.
Capacity Expansion: Dahej facility providing additional capacity; Sotanala project progressing as planned, with formulation facility expected to commence around April-May next year. Total Sotanala capex estimated at ~₹200 crores (₹70 crores invested to date), targeting 5-6 molecules in the first phase.
Distribution & Farmer Engagement: Conducted 3,600+ formal meetings, 600 field days, 1,400 demonstrations, and 15,000+ formal visits, supported by 8,500+ distributors and 70,000+ retail customers.
IL Crop Solution Program: Plans to double the number of plots, expanding presence across 14 states and several crops including rice, cotton, kiwi, and soybean.
Efficiency Initiatives: Renewable energy and fuel consumption measures expected to provide efficiency benefits from Q3 onwards, reducing power and steel costs.

Guidance & Outlook

Metric	Guidance / Outlook	Commentary
Sales Growth	Positive from Q2 onwards	Delayed demand is deferred, not lost; management expects stronger execution in remaining three quarters
Revenue Doubling	Double in 4-5 years	Driven by product mix, technical manufacturing, and backward integration
Capex	₹30-40 crores annual maintenance capex	Expected to normalize after current projects are completed
Sotanala Plant	Commencement around April-May 2027	Formulation facility first, followed by treatment products production
Sales Returns	Reduce by at least half YoY	Prudent placement strategy; limited herbicide returns expected this year
Working Capital	Substantial improvement in Q2	Inventory from June is being liquidated; weekly management meetings on capital efficiency

Risks & Constraints

Risk	Context
Delayed/Uneven Monsoon	Impacted sowing activity and delayed demand for crop protection products in Q1; management sees recovery but south India rice sowing remains a gap
Raw Material Price Volatility	Solvent prices fluctuating 25-30% week-to-week; plastic and freight costs impacted by supply chain disruption, affecting gross margins
Pricing Pressure	Market sentiment weak; price hikes taken in March and April were partially rolled back in July; ability to pass on cost increases limited
Sales Returns	Possibility of returns exists, but lower than prior year due to cautious placement strategy
Margin Compression in New Businesses	CARO Research margins are at single digits; profitability will remain lower until scale is achieved

Q&A Highlights

Capacity Expansion & Capex

Question: What is the total investment in Sotanala formulation and technical plant? (Prashant Biyani, Elara Securities)
Answer: Total investment ~₹200 crores, with ~₹50 crores for formulations and the balance for technicals. ~₹70 crores invested to date. Five to six products identified for first phase. (Rajesh Kumar Aggarwal, MD)

Demand Environment & Sales Outlook

Question: How do you see the demand environment going forward? (Ramesh, S.J. Investments)
Answer: August had three good rains; reservoirs improving; crops healthy. South India rice sowing remains a gap but improving. Overall sales growth should be positive from Q2 onwards. (Rajesh Kumar Aggarwal, MD)

Premium vs. Generic Brands

Question: Could you explain the customer segmentation between Maharatna and Focus Maharatna products versus generic products? (Ramesh, S.J. Investments)
Answer: Farmer acceptance depends on awareness and ROI demonstration. Even small farmers adopt premium products if economics are compelling. Premium contribution has grown from 48% five years back to over 60% now. Target 70% in 3-4 years. (Rajesh Kumar Aggarwal, MD)

B2B Growth & Inventory Gains

Question: Was there inventory gain contributing to B2B growth and gross margin expansion? (Madhur Rathi, Counter Cyclical Investments)
Answer: Some advantage from older inventories, but price hikes could not be sustained due to weak demand sentiment. Price hikes taken in March and April were partially rolled back in July. Volatility in input costs was extreme. (Rajesh Kumar Aggarwal, MD)

Volume Growth

Question: What was volume growth for B2B and B2C? (Kunal Tokas, Fair Value Capital)
Answer: Overall volume degrowth ~13%; B2B showed slightly more growth than B2C. B2B expected to grow faster in Q2 as well. (Rajesh Kumar Aggarwal, MD)

Sales Returns

Question: Are we expecting a situation with sales returns like last year's ₹200 crores? (Kunal Tokas, Fair Value Capital)
Answer: Return possibilities exist, but placements were cautious this year. Should be able to reduce returns to at least half of previous year. (Rajesh Kumar Aggarwal, MD)

Product-Level Revenue Expectations

Question: What is the revenue expectation from Granular and Spino ace for FY27? (Sonia Raghuvanshi, Nirma Securities)
Answer: Granular can touch ~₹20 crores and Spino ace ~₹10 crores+ this fiscal, totaling ₹30-35 crores gross (₹25 crores net). Q1 revenue from these products was ~₹5 crores. (Rajesh Kumar Aggarwal, MD)

Segment-Wise Sales

Question: How did the herbicide portfolio perform, and what is the segment-wise revenue mix? (Sonia Raghuvanshi, Nirma Securities)
Answer: Insecticide at 33%, herbicide at 59%, fungicide at 5%, and PGR at 3% of B2C sales in Q1. Herbicide growth likely to register in Q2 due to delayed demand. (Sandeep Kumar Aggarwal, CFO)

Gross Margin Expansion Drivers

Question: Could you break down gross margin expansion between pricing, mix, and inventory gains? (Paul Sharma, DD Capital)
Answer: Mix of price increases, specialty product focus, and some inventory advantage. Input cost volatility was extreme with solvent prices fluctuating widely. Expect margin stability as demand normalizes post-August. (Rajesh Kumar Aggarwal, MD)

Working Capital

Question: What is the status of the working capital cycle? (Nivesh Verma, AKS Capital - partial due to connectivity)
Answer: Management is focused on improving inventory turns, collections, and cash generation. Inventory from June is being liquidated effectively; substantial improvement expected in Q2. (Partially captured due to audio issues)

Key Takeaway

Q1 FY27 was a challenging quarter for Insecticides India, with revenue growing only 2% (volume degrowth of 13%) as delayed monsoons and uneven sowing patterns pushed demand for crop protection products into subsequent quarters. Despite the soft top-line, gross margin expanded 240 bps to 31.6%, supported by premium product mix and some inventory gains, though EBITDA margin contracted 310 bps to 9.1%. The company is leaning on its 64% contribution from Maharatna and Focus Maharatna products, a pipeline of 30+ product launches over the next two years, and expanding international opportunities to drive recovery. The Sotanala capex (₹200 crores total) is progressing, with formulation capacity expected by April-May next year, after which annual capex will normalize to ₹30-40 crores. Management expects positive growth from Q2 onwards as August rains improved reservoir levels and kharif sowing accelerates, with focus on working capital discipline and improving ROE as utilization improves. Key watch points include input cost volatility, pricing power in a competitive market, and execution of the premiumization strategy toward the 70% contribution target.